Putative biomarker genes for grading clear cell renal cell carcinoma

Urologia Internationalis

Volumn 87, Issue 2, 2011, Pages 205-217

  Maruschke, M ^a   Koczan, D ^b   Reuter, D ^b   Ziems, B ^c   Nizze, H ^a   Hakenberg, O W ^a   Thiesen, H J ^b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b Institute of Immunology   (Germany)

^c Gesellschaft für Individualisierte Medizin GmbH   (Germany)

Author keywords

Ceruloplasmin; Event ratio scoring; Gene expression; Metastasis; Prognostic factors; Renal cell carcinoma

Indexed keywords

RNA;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER TISSUE; CLEAR CELL RENAL CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE CLUSTER; GENE EXPRESSION; GENE IDENTIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; TUMOR GENE; UPREGULATION;

AGED; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CERULOPLASMIN; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RNA; TUMOR MARKERS, BIOLOGICAL;

EID: 80052720327     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000328196     Document Type: Article

References (47)

1. Jemal A, Clegg LX, Ward E, et al: Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004; 101: 3-27. (Pubitemid 38812419)
2. Amin MB, Amin MB, Tamboli P, et al: Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: An experience of 405 cases. Am J Surg Pathol 2002; 26: 281-291. (Pubitemid 34184451)
3. Moch H, Gasser T, Amin MB, et al: Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: A Swiss experience with 588 tumors. Cancer 2000; 89: 604-614. (Pubitemid 30640107)
4. Janzen NK, Kim HL, Figlin RA, et al: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003; 30: 843-845.
5. Zisman A, Pantuck AJ, Dorey F, et al: Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001; 19: 1649-1657. (Pubitemid 32230864)
6. Bukowski RM: Metastatic clear cell carcinoma of the kidney: Therapeutic role of bevacizumab. Cancer Manag Res 2010; 2: 83-96.
7. Cella D, Michaelson MD, Bushmakin AG, et al: Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: Final results and geographical analysis. Br J Cancer 2010; 102: 658-664.
8. Jones J, Otu H, Spentzos D, et al: Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 2005; 11: 5730-5739. (Pubitemid 41170297)
9. Jones J, Libermann TA: Genomics of renal cell cancer: The biology behind and the therapy ahead. Clin Cancer Res 2007; 13: 685s-692s.
10. Sültmann H, von Heydebreck A, Huber W, et al: Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival. Clin Cancer Res 2005; 11: 646-655. (Pubitemid 40116891)
11. Maruschke M, Reuter D, Koczan D, Hakenberg OW, Thiesen HJ: Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management. BJU Int DOI: 10.1111/j.1464-410X.2010. 09794.x.
12. Aris VM, Cody MJ, Cheng J, et al: Noise filtering and nonparametric analysis of microarray data underscores discriminating markers of oral, prostate, lung, ovarian and breast cancer. BMC Bioinformatics 2004; 5: 185.
13. Eisen MB, Spellman PT, Brown PO, et al: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863-14868. (Pubitemid 29003722)
14. Eichelberg C, Junker K, Ljungberg B, et al: Diagnostic and prognostic molecular markers for renal cell carcinoma: A critical appraisal of the current state of research and clinical applicability. Eur Urol 2009; 55: 851-863.
15. Zhu YY, Takashi M, Miyake, et al: An immunochemical and immunohistochemical study of aldolase isozymes in renal cell carcinoma. J Urol 1991; 146: 469-472.
16. Ikeda JI, Morii E, Kimura H, et al: Epigenetic regulation of the expression of the novel stem cell marker CDCP1 in cancer cells. J Pathol 2006; 210: 75-84. (Pubitemid 44288183)
17. Uekita T, Jia L, Narisawa-Saito M, et al: CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. Mol Cell Biol 2007; 27: 7649-7660. (Pubitemid 350033670)
18. Warth A, Mittelbronn M, Hülper P, et al: Expression of the water channel protein aquaporin-9 in malignant brain tumors. Appl Immunohistochem Mol Morphol 2007; 15: 193-198. (Pubitemid 46828228)
19. Carbrey JM, Gorelick-Feldman DA, Kozono D, Praetorius J, Nielsen S, Agre P: Aquaglyceroporin AQP9: Solute permeation and metabolic control of expression in liver. Proc Natl Acad Sci USA 2003; 100: 2945-2950. (Pubitemid 36297603)
20. Kramer MW, Merseburger AS, Tezval H: Can aquaporin-1 and adipophilin in urine distinguish between malignant and nonmalignant renal lesions? Mayo Clin Proc 2010; 85: 768; author reply 768-769.
21. Grebe SK, Erickson LA: Screening for kidney cancer: Is there a role for aquaporin-1 and adipophilin? Mayo Clin Proc 2010; 85: 410-412.
22. Wu CC, Shyu RY, Chou JM, et al: RARRES1 expression is significantly related to tumour differentiation and staging in colorectal adenocarcinoma. Eur J Cancer 2006; 42: 557-565.
23. Hewett D, Samuelsson L, Polding J, et al: Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map. Genomics 2002; 79: 305-314. (Pubitemid 34211938)
24. Dunn LL, Sekyere EO, Rahmanto YS, et al: The function of melanotransferrin: A role in melanoma cell proliferation and tumorigenesis. Carcinogenesis 2006; 27: 2157-2169. (Pubitemid 44644804)
25. Bertrand Y, Demeule M, Michaud-Levesque J, et al: Melanotransferrin induces human melanoma SK-Mel-28 cell invasion in vivo. Biochem Biophys Res Commun 2007; 353: 418-423. (Pubitemid 46014579)
26. Kimura M, Tomita Y, Imai T, et al: Significance of serum amyloid A on the prognosis in patients with renal cell carcinoma. Cancer 2001; 92: 2072-2075. (Pubitemid 32973316)
27. Song JY, Lee JK, Lee NW, et al: Microarray analysis of normal cervix, carcinoma in situ, and invasive cervical cancer: Identification of candidate genes in pathogenesis of invasion in cervical cancer. Int J Gynecol Cancer 2008; 18: 1051-1059.
28. Blumberg H, Conklin D, Xu WF, et al: Interleukin 20: Discovery, receptor identification, and role in epidermal function. Cell 2001; 104: 9-19. (Pubitemid 32144968)
29. Liu L, Ding C, Zeng W, et al: Selective enhancement of multipotential hematopoietic progenitors in vitro and in vivo by IL-20. Blood 2003; 102: 3206-3209. (Pubitemid 37314757)
30. Hsieh MY, Chen WY, Jiang MJ, et al: Interleukin-20 promotes angiogenesis in a direct and indirect manner. Genes Immun 2006; 7: 234-242.
31. Hou Z, Zhou J, Ma X, et al: Role of interleukin-1 receptor type II in the pathogenesis of endometriosis. Fertil Steril 2008; 89: 42-51.
32. Walther MM, Patel B, Choyke PL, et al: Hypercalcemia in patients with metastatic renal cell carcinoma: Effect of nephrectomy and metabolic evaluation. J Urol 1997; 158: 733-739.
33. Ueno M, Tokonabe S, Kuroda I, et al: Hypercalcemia upon recurrence of renal cell carcinoma producing parathyroid hormone-related protein. Scand J Urol Nephrol 2003; 37: 265-268. (Pubitemid 36791828)
34. Papworth K, Grankvist K, Ljungberg B, Rasmuson T: Parathyroid hormone-related protein and serum calcium in patients with renal cell carcinoma. Tumour Biol 2005; 26: 201-206. (Pubitemid 41379746)
35. Rissanen J, Korhonen M, Lehto VP, et al: Laminin alpha1 chain in human renal cell carcinomas and integrin-mediated adhesion of renal cell carcinoma cells to human laminin isoforms. J Pathol 2003; 200: 157-167. (Pubitemid 36748024)
36. Tran M, Rousselle P, Nokelainen P, et al: Targeting a tumor-specific laminin domain critical for human carcinogenesis. Cancer Res 2008; 68: 2885-2894. (Pubitemid 351556288)
37. Martin F, Linden T, Katschinski DM, et al: Copper-dependent activation of hypoxia-inducible factor (HIF)-1: Implications for ceruloplasmin regulation. Blood 2005; 105: 4613-4619. (Pubitemid 40807279)
38. Shukla N, Maher J, Masters J, et al: Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor̂ Atherosclerosis 2006; 187: 238-250. (Pubitemid 43963031)
39. Osunkoya AO, Yin-Goen Q, Phan JH, et al: Diagnostic biomarkers for renal cell carcinoma: Selection using novel bioinformatics systems for microarray data analysis. Hum Pathol 2009; 40: 1671-1678.
40. Koschinsky ML, Funk WD, van Oost BA, MacGillivray RT: Complete cDNA sequence of human preceruloplasmin. Proc Natl Acad Sci USA 1986; 83: 5086-5090. (Pubitemid 16051321)
41. Healy J, Tipton K: Ceruloplasmin and what it might do. J Neural Transm 2007; 114: 777-781. (Pubitemid 46980484)
42. Mukhopadhyay CK, Mazumder B, Fox PL: Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency. J Biol Chem 2000; 275: 21048-21054. (Pubitemid 30481794)
43. Hellman NE, Gitlin JD: Ceruloplasmin metabolism and function. Annu Rev Nutr 2002; 22: 439-458. (Pubitemid 35221468)
44. Bento I, Peixoto C, Zaitsev VN, Lindley PF: Ceruloplasmin revisited: Structural and functional roles of various metal cationbinding sites. Acta Crystallogr D Biol Crystallogr 2007; 63: 240-248. (Pubitemid 46197541)
45. Das D, Tapryal N, Goswami SK, Fox PL, Mukhopadhyay CK: Regulation of ceruloplasmin in human hepatic cells by redox active copper: Identification of a novel AP-1 site in the ceruloplasmin gene. Biochem J 2007; 402: 135-141.
46. Vasselli JR, Shih JH, Iyengar SR, et al: Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci USA 2003; 100: 6958-6963. (Pubitemid 36706375)
47. Kosari F, Parker AS, Kube DM, et al: Clear cell renal cell carcinoma: Gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res 2005; 11: 5128-5139. (Pubitemid 41003697)